Osmotica Pharmaceuticals (OSMT) Upgraded at Zacks Investment Research

Osmotica Pharmaceuticals (NASDAQ:OSMT) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Tuesday, Zacks.com reports.

According to Zacks, “Osmotica Pharmaceuticals Public Limited Company operates as a biopharmaceutical company. It offers tablets, dietary supplements and drugs for the treatment of women’s health. The company’s product pipeline consists of Methylphenidate HCl ER 72 mg Tablets, Osmolex ER(TM), Lorzone(R), ConZip(R), Divigel(R) and OB Complete(R). Its delivery system includes Osmodex(R) drug delivery system. Osmotica Pharmaceuticals Public Limited Company is based in Bridgewater, New Jersey. “

Separately, Wells Fargo & Co set a $14.00 target price on shares of Osmotica Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, March 28th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $15.50.

Shares of OSMT opened at $2.62 on Tuesday. The company has a market capitalization of $130.35 million and a P/E ratio of -5.14. The company has a current ratio of 1.51, a quick ratio of 1.29 and a debt-to-equity ratio of 0.69. Osmotica Pharmaceuticals has a 1-year low of $2.41 and a 1-year high of $9.90.

Osmotica Pharmaceuticals (NASDAQ:OSMT) last announced its earnings results on Thursday, May 9th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.08). The company had revenue of $57.13 million for the quarter, compared to analyst estimates of $53.58 million. On average, analysts anticipate that Osmotica Pharmaceuticals will post 0.07 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. OppenheimerFunds Inc. raised its stake in Osmotica Pharmaceuticals by 16.2% in the first quarter. OppenheimerFunds Inc. now owns 38,890 shares of the company’s stock valued at $140,000 after purchasing an additional 5,416 shares in the last quarter. American International Group Inc. purchased a new stake in Osmotica Pharmaceuticals in the fourth quarter valued at approximately $50,000. SG Americas Securities LLC purchased a new stake in Osmotica Pharmaceuticals in the first quarter valued at approximately $45,000. Acadian Asset Management LLC purchased a new position in shares of Osmotica Pharmaceuticals during the first quarter worth approximately $52,000. Finally, Deutsche Bank AG purchased a new position in shares of Osmotica Pharmaceuticals during the fourth quarter worth approximately $111,000. 12.78% of the stock is currently owned by institutional investors and hedge funds.

About Osmotica Pharmaceuticals

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.

Featured Article: Short Selling Stocks and Day Traders

Get a free copy of the Zacks research report on Osmotica Pharmaceuticals (OSMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.